Skip to Content
MilliporeSigma
  • Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country.

Medication errors on oral chemotherapy in children with acute lymphoblastic leukemia in a developing country.

Pediatric blood & cancer (2014-09-02)
Sapna Oberoi, Amita Trehan, Ram Kumar Marwaha
ABSTRACT

Medication errors occur universally. Inappropriate administration of chemotherapy drugs can have adverse effects in cancer patients. Our objective was to assess the rate and type of medication errors in children with acute lymphoblastic leukemia (ALL) receiving oral chemotherapy in outpatient setting. Prescription and administration of oral chemotherapy drugs in children with ALL were evaluated prospectively to determine rate and type of medication errors. Errors were defined as prescription (physician) level or administration (patient) level errors. Two hundred eighty-nine drugs were prescribed to 121 patients. Medication errors occurred in 36 (12.5%) prescriptions; 21(7.3%) were administration errors, 13 (4.5%) were prescribing errors, and two errors occurred at both levels. Mercaptopurine (6-MP) was significantly associated with higher rates of errors (Odds ratio [OR] = 2.1, 95% CI [confidence interval] 1-4.1) whereas lapses were less with dexamethasone (OR = 0.25, 95% CI 0.09-0.67). As a result of medication errors 28 (23.1%) patients received inappropriate doses. Twenty five (21%) patients received sub-optimal doses whereas three got higher doses of chemotherapy. On univariate analysis, socioeconomic status, education status of the caregiver, 6-MP and methotrexate were significantly associated with errors (P ≤ 0.05). On multivariate analysis, ≤ primary school education of the caregiver and prescription of methotrexate were independent predictors of errors. Medication errors affected nearly one fourth of the children receiving oral chemotherapy. Future studies are needed to look at effective interventions to avoid chemotherapy associated errors especially amongst the lower strata of society.

MATERIALS
Product Number
Brand
Product Description

Supelco
Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
6-Mercaptopurine monohydrate, 98%
Dexamethasone for peak identification, European Pharmacopoeia (EP) Reference Standard
Methotrexate for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Methotrexate hydrate, ≥99.0% (sum of enantiomers, HPLC)
Supelco
Dexamethasone, VETRANAL®, analytical standard
Sigma-Aldrich
Dexamethasone, tested according to Ph. Eur.
Sigma-Aldrich
Methotrexate hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Methotrexate hydrate, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Dexamethasone, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Sigma-Aldrich
Methotrexate, meets USP testing specifications
Sigma-Aldrich
Dexamethasone, ≥98% (HPLC), powder
Sigma-Aldrich
Dexamethasone, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Dexamethasone, meets USP testing specifications
Sigma-Aldrich
Dexamethasone-Water Soluble, suitable for cell culture, BioReagent
Supelco
Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard
Dexamethasone, European Pharmacopoeia (EP) Reference Standard
Supelco
Dexamethasone, Pharmaceutical Secondary Standard; Certified Reference Material
Dexamethasone for system suitability, European Pharmacopoeia (EP) Reference Standard
SAFC
Methotrexate
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Supelco
Methotrexate, Pharmaceutical Secondary Standard; Certified Reference Material